Gene Silencing Porphyria Treatment, Givlaari, Finally Wins Over England’s NICE Amid Stellar Long-Term Data
XTalks
OCTOBER 26, 2021
NICE’s reversed recommendation comes on the heels of new long-term results for the treatment released by Givlaari maker Alnylam Pharmaceuticals. The treatment came with an initial price tag of $39,000 per vial, which amounts to a total of $575,00 each year.
98 
Let's personalize your content